scholarly journals 2272. High Interest in Doxycycline for Sexually Transmitted Infection Post-Exposure Prophylaxis (Doxy-PEP) in a Multi-city Survey of Men Having Sex With Men (MSM) Using a Social-Networking App

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S672-S673
Author(s):  
Matthew A Spinelli ◽  
Hyman Scott ◽  
Eric Vittinghoff ◽  
Albert Y Liu ◽  
Kenneth Coleman ◽  
...  
Keyword(s):  
Social Networking ◽  
Sexually Transmitted Infection ◽  
Post Exposure Prophylaxis ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Post Exposure ◽  
High Interest ◽  
Sex With Men ◽  
Exposure Prophylaxis

scholarly journals Sexually transmitted infection diagnoses, sexualised drug use and associations with pre-exposure prophylaxis use among men who have sex with men in the UK

2020 ◽  
Vol 31 (3) ◽  
pp. 254-263
Author(s):  
Matthew P Hibbert ◽  
Caroline E Brett ◽  
Lorna A Porcellato ◽  
Vivian D Hope
Keyword(s):  
Drug Use ◽  
Sexually Transmitted Infection ◽  
Transmitted Infection ◽  
Cross Sectional ◽  
Sexually Transmitted ◽  
Factors Associated ◽  
Hiv Test ◽  
Condomless Anal Intercourse ◽  
Sex With Men ◽  
Exposure Prophylaxis

Previous research has focused on acceptability of pre-exposure prophylaxis (PrEP) use, but few community-based studies have been conducted regarding actual use, and PrEP use in the context of sexualised drug use remains understudied. A national online cross-sectional study recruited men who have sex with men (MSM) via social media (April–June 2018). Multivariable logistic regression was used to investigate factors associated with PrEP use. Bivariate analyses compared engaging in condomless anal intercourse (CAI) under the influence of specific drugs and recent sexually transmitted infection (STI) diagnoses (past 12 months) between MSM taking PrEP and those not. Overall, 6% (99/1581) MSM reported current PrEP use. Factors associated with PrEP use were increasing age, recent genitourinary medicine (GUM) attendance (95% versus 45%, aOR = 6.25, 95%CI 2.05, 19.03), an HIV test in the past three months (89% versus 23%, aOR = 14.22, 95%CI 6.76, 29.90), and recent engagement in chemsex (21% versus 4%, aOR = 3.56, 95%CI 1.78, 7.11). MSM taking PrEP were more likely to have had an STI diagnosis (42% versus 8%), most commonly chlamydia (26% versus 3%) and gonorrhoea (25% versus 4%). Considering the elevated levels of self-reported STI diagnoses among those on PrEP, there was a high level of engagement with sexual health services, which may help reduce onward STI transmission.

scholarly journals Gaps in Sexually Transmitted Infection Screening Among Men who Have Sex with Men in Pre-exposure Prophylaxis (PrEP) Care in the United States

2020 ◽  
Author(s):  
Christina Chandra ◽  
Kevin M Weiss ◽  
Colleen F Kelley ◽  
Julia L Marcus ◽  
Samuel M Jenness
Keyword(s):  
United States ◽  
Clinical Practice ◽  
Sexually Transmitted Infection ◽  
Prevalence Ratio ◽  
The United States ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Exposure Site ◽  
Sex With Men ◽  
Exposure Prophylaxis

Abstract Background The US Centers for Disease Control and Prevention (CDC) recommends comprehensive sexually transmitted infection (STI) screening every 3–6 months for men who have sex with men (MSM) using human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP). The gaps between these recommendations and clinical practice by region have not been quantified. Methods We used survey data collected from the internet-based ARTnet study between 2017 and 2019 on STI screening among MSM across the United States, stratified by current, prior, and never PrEP use. Poisson regression models with robust error variance were used to model factors, including residence in the Southeast, associated with consistent (“always” or “sometimes”) exposure site-specific STI screening during PrEP care. Results Of 3259 HIV-negative MSM, 19% were currently using PrEP, 6% had used PrEP in the past, and 75% had never used PrEP. Among ever PrEP users, 87%, 78%, 57%, and 64% reported consistent screening for STIs by blood sample, urine sample or urethral swab, rectal swab, or pharyngeal swab, respectively, during PrEP care. Compared to PrEP users in all other regions, PrEP users in the Southeast were significantly less likely to be consistently screened for urogenital (adjusted prevalence ratio [aPR], 0.86; 95% confidence interval [CI], .76–.98) and rectal STIs (aPR, 0.76; 95% CI, .62–.93) during PrEP care. Conclusions Substantial gaps exist between CDC recommendations for STI screening during PrEP care and current clinical practice, particularly for rectal and pharyngeal exposure sites that can harbor asymptomatic infections and for MSM in Southeast states where the STI burden is substantial.

Sign in / Sign up

Export Citation Format

Share Document